Correction: SETD2 loss sensitizes cells to PI3Kβ and AKT inhibition

Oncotarget. 2019 Oct 29;10(59):6391-6392. doi: 10.18632/oncotarget.27288.

Esteban A Terzo^{1

2

3}, Aaron R Lim^{1

4

3}, Anna Chytil¹, Yun Chen Chiang^{5

6}, Leah Farmer¹, Kathryn H Gessner⁵, Cheryl Lyn Walker⁷, Valerie M Jansen^{1

8

9}, W Kimryn Rathmell^{1

9}

¹ Vanderbilt-Ingram Cancer Center, Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville 37232, TN, USA.
² Current Address: Constellation Pharmaceuticals, Cambridge, MA, USA.
³ Co-first authors.
⁴ Medical Scientist Training Program, Vanderbilt University School of Medicine, Nashville 37232, TN, USA.
⁵ Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill 27599, NC, USA.
⁶ Current Address: Novella/IQVIA, Morrisville, NC, USA.
⁷ Center for Precision Environmental Health, Baylor College of Medicine, Houston 77030, TX, USA.
⁸ Current Address: Eli Lilly and Company, Indianapolis, IN, USA.
⁹ Co-corresponding authors.

Abstract

[This corrects the article DOI: 10.18632/oncotarget.26567.].